59 results
Page 2 of 3
8-K
EX-99.1
ykqw1i
7 Dec 23
Regulation FD Disclosure
9:20am
8-K
EX-99.1
sl1 a0mcl4t
13 Nov 23
NeuroBo Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:14pm
8-K
EX-99.1
byo5m
6 Nov 23
Departure of Directors or Certain Officers
8:20am
8-K
EX-99.1
hs3 87s0lwl7p1
15 Sep 23
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
8:11am
8-K
EX-99.1
b2hdlb52drohoziaw450
9 Aug 23
NeuroBo Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:20pm
8-K
EX-99.1
gqgym6mkml
3 Aug 23
NeuroBo Pharmaceuticals Receives First Site IRB Approval for its
8:15am
8-K
EX-99.1
zg6qbxaqh6l
27 Jun 23
Other Events
8:26am
8-K
EX-99.1
s25ghuwf6ev lb2
13 Jun 23
Other Events
8:25am
8-K
EX-99.1
5jyyjubjc8
12 May 23
Departure of Directors or Certain Officers
8:13am
8-K
EX-99.1
lztq2f2lhpkyl9op
2 May 23
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH
8:18am
8-K
EX-99.1
fct7jck2br8oea
3 Apr 23
NeuroBo Pharmaceuticals Announces Submission of IND Application to the FDA for a Phase 2a Clinical Trial of DA-1241 for the Treatment of NASH
8:14am
424B4
ranrxyfp5o
7 Nov 22
Prospectus supplement with pricing info
9:07am